Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 1/2020

01.01.2020 | Original Article

GCN2 is essential for CD8+ T cell survival and function in murine models of malignant glioma

verfasst von: Aida Rashidi, Jason Miska, Catalina Lee-Chang, Deepak Kanojia, Wojciech K. Panek, Aurora Lopez-Rosas, Peng Zhang, Yu Han, Ting Xiao, Katarzyna C. Pituch, Julius W. Kim, Mahsa Talebian, Jawad Fares, Maciej S. Lesniak

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Amino acid deprivation is a strategy that malignancies utilize to blunt anti-tumor T-cell immune responses. It has been proposed that amino acid insufficiency in T-cells is detected by GCN2 kinase, which through phosphorylation of EIF2α, shuts down global protein synthesis leading to T-cell arrest. The role of this amino acid stress sensor in the context of malignant brain tumors has not yet been studied, and may elucidate important insights into the mechanisms of T-cell survival in this harsh environment. Using animal models of glioblastoma and animals with deficiency in GCN2, we explored the importance of this pathway in T-cell function within brain tumors. Our results show that GCN2 deficiency limited CD8+ T-cell activation and expression of cytotoxic markers in two separate murine models of glioblastoma in vivo. Importantly, adoptive transfer of antigen-specific T-cells from GCN2 KO mice did not control tumor burden as well as wild-type CD8+ T-cells. Our in vitro and in vivo data demonstrated that reduction in amino acid availability caused GCN2 deficient CD8+ T-cells to become rapidly necrotic. Mechanistically, reduced CD8+ T-cell activation and necrosis was due to a disruption in TCR signaling, as we observed reductions in PKCθ and phoshpo-PKCθ on CD8+ T-cells from GCN2 KO mice in the absence of tryptophan. Validating these observations, treatment of wild-type CD8+ T-cells with a downstream inhibitor of GCN2 activation also triggered necrosis of CD8+ T-cells in the absence of tryptophan. In conclusion, our data demonstrate the vital importance of intact GCN2 signaling on CD8+ T-cell function and survival in glioblastoma.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Rashidi A, Miska J, Pituch K, Kanojia D, Lopez-Rosas A, Han Y et al (2017) Gcn2 kinase is essential for adaptive T-cell immunity in glioma. Neuro-Oncology 19:113 Rashidi A, Miska J, Pituch K, Kanojia D, Lopez-Rosas A, Han Y et al (2017) Gcn2 kinase is essential for adaptive T-cell immunity in glioma. Neuro-Oncology 19:113
2.
Zurück zum Zitat Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122–133PubMedPubMedCentral Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122–133PubMedPubMedCentral
3.
Zurück zum Zitat Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M et al (2018) Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 36(8):773–779PubMed Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M et al (2018) Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 36(8):773–779PubMed
4.
Zurück zum Zitat Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB et al (2019) Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 25(3):477–486PubMedPubMedCentral Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB et al (2019) Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 25(3):477–486PubMedPubMedCentral
5.
Zurück zum Zitat Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH et al (2018) T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin Cancer Res 24(17):4175–4186PubMedPubMedCentral Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH et al (2018) T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin Cancer Res 24(17):4175–4186PubMedPubMedCentral
6.
Zurück zum Zitat Mirzaei R, Sarkar S, Yong VW (2017) T cell exhaustion in glioblastoma: intricacies of immune checkpoints. Trends Immunol 38(2):104–115PubMed Mirzaei R, Sarkar S, Yong VW (2017) T cell exhaustion in glioblastoma: intricacies of immune checkpoints. Trends Immunol 38(2):104–115PubMed
7.
8.
Zurück zum Zitat Kwidzinski E, Bunse J, Aktas O, Richter D, Mutlu L, Zipp F et al (2005) Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. Faseb J. 19(8):1347PubMed Kwidzinski E, Bunse J, Aktas O, Richter D, Mutlu L, Zipp F et al (2005) Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. Faseb J. 19(8):1347PubMed
9.
Zurück zum Zitat Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B et al (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281(5380):1191–1193PubMed Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B et al (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281(5380):1191–1193PubMed
10.
Zurück zum Zitat Lob S, Konigsrainer A, Zieker D, Brucher BL, Rammensee HG, Opelz G et al (2009) IDO1 and IDO2 are expressed in human tumors: levo—but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 58(1):153–157PubMed Lob S, Konigsrainer A, Zieker D, Brucher BL, Rammensee HG, Opelz G et al (2009) IDO1 and IDO2 are expressed in human tumors: levo—but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 58(1):153–157PubMed
11.
Zurück zum Zitat Dong J, Qiu H, Garcia-Barrio M, Anderson J, Hinnebusch AG (2000) Uncharged tRNA activates GCN2 by displacing the protein kinase moiety from a bipartite tRNA-binding domain. Mol Cell 6(2):269–279PubMed Dong J, Qiu H, Garcia-Barrio M, Anderson J, Hinnebusch AG (2000) Uncharged tRNA activates GCN2 by displacing the protein kinase moiety from a bipartite tRNA-binding domain. Mol Cell 6(2):269–279PubMed
12.
Zurück zum Zitat Garcia-Barrio M, Dong J, Ufano S, Hinnebusch AG (2000) Association of GCN1-GCN20 regulatory complex with the N-terminus of eIF2alpha kinase GCN2 is required for GCN2 activation. EMBO J 19(8):1887–1899PubMedPubMedCentral Garcia-Barrio M, Dong J, Ufano S, Hinnebusch AG (2000) Association of GCN1-GCN20 regulatory complex with the N-terminus of eIF2alpha kinase GCN2 is required for GCN2 activation. EMBO J 19(8):1887–1899PubMedPubMedCentral
13.
Zurück zum Zitat Fusakio ME, Willy JA, Wang Y, Mirek ET, Al Baghdadi RJ, Adams CM et al (2016) Transcription factor ATF4 directs basal and stress-induced gene expression in the unfolded protein response and cholesterol metabolism in the liver. Mol Biol Cell 27(9):1536–1551PubMedPubMedCentral Fusakio ME, Willy JA, Wang Y, Mirek ET, Al Baghdadi RJ, Adams CM et al (2016) Transcription factor ATF4 directs basal and stress-induced gene expression in the unfolded protein response and cholesterol metabolism in the liver. Mol Biol Cell 27(9):1536–1551PubMedPubMedCentral
14.
Zurück zum Zitat Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M et al (2000) Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell 6(5):1099–1108PubMed Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M et al (2000) Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell 6(5):1099–1108PubMed
15.
Zurück zum Zitat Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM (2016) The integrated stress response. EMBO Rep 17(10):1374–1395PubMedPubMedCentral Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM (2016) The integrated stress response. EMBO Rep 17(10):1374–1395PubMedPubMedCentral
16.
Zurück zum Zitat Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B et al (2012) IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 18(22):6110–6121PubMedPubMedCentral Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B et al (2012) IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res 18(22):6110–6121PubMedPubMedCentral
17.
Zurück zum Zitat Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim C, Tobias AL et al (2014) Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors. Clinical Cancer Research. 20:5290–5301PubMedPubMedCentral Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim C, Tobias AL et al (2014) Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors. Clinical Cancer Research. 20:5290–5301PubMedPubMedCentral
18.
Zurück zum Zitat Holmgaard RB, Zamarin D, Li YY, Gasmi B, Munn DH, Allison JP et al (2015) Tumor-expressed IDO recruits and activates MDSCs in a treg-dependent manner. Cell Rep 13(2):412–424PubMedPubMedCentral Holmgaard RB, Zamarin D, Li YY, Gasmi B, Munn DH, Allison JP et al (2015) Tumor-expressed IDO recruits and activates MDSCs in a treg-dependent manner. Cell Rep 13(2):412–424PubMedPubMedCentral
19.
Zurück zum Zitat Yu JP, Du WJ, Yan F, Wang Y, Li H, Cao S et al (2013) Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 190(7):3783–3797PubMed Yu JP, Du WJ, Yan F, Wang Y, Li H, Cao S et al (2013) Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 190(7):3783–3797PubMed
20.
Zurück zum Zitat Miret JJ, Kirschmeier P, Koyama S, Zhu M, Li YY, Naito Y et al (2019) Suppression of myeloid cell arginase activity leads to therapeutic response in a NSCLC mouse model by activating anti-tumor immunity. J Immunother Cancer 7(1):32PubMedPubMedCentral Miret JJ, Kirschmeier P, Koyama S, Zhu M, Li YY, Naito Y et al (2019) Suppression of myeloid cell arginase activity leads to therapeutic response in a NSCLC mouse model by activating anti-tumor immunity. J Immunother Cancer 7(1):32PubMedPubMedCentral
21.
Zurück zum Zitat Lind DS (2004) Arginine and cancer. J Nutr. 134(10 Suppl):2837S–2841S (discussion 53S) PubMed Lind DS (2004) Arginine and cancer. J Nutr. 134(10 Suppl):2837S–2841S (discussion 53S) PubMed
22.
Zurück zum Zitat Caso G, McNurlan MA, McMillan ND, Eremin O, Garlick PJ (2004) Tumour cell growth in culture: dependence on arginine. Clin Sci (Lond) 107(4):371–379 Caso G, McNurlan MA, McMillan ND, Eremin O, Garlick PJ (2004) Tumour cell growth in culture: dependence on arginine. Clin Sci (Lond) 107(4):371–379
23.
Zurück zum Zitat Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T et al (2016) l-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. 167(3):829–842.e13PubMedPubMedCentral Geiger R, Rieckmann JC, Wolf T, Basso C, Feng Y, Fuhrer T et al (2016) l-Arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. 167(3):829–842.e13PubMedPubMedCentral
24.
Zurück zum Zitat Zhang J, Fan J, Venneti S, Cross JR, Takagi T, Bhinder B et al (2014) Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. Mol Cell 56(2):205–218PubMedPubMedCentral Zhang J, Fan J, Venneti S, Cross JR, Takagi T, Bhinder B et al (2014) Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. Mol Cell 56(2):205–218PubMedPubMedCentral
25.
Zurück zum Zitat Pavlova NN, Hui S, Ghergurovich JM, Fan J, Intlekofer AM, White RM et al (2018) As extracellular glutamine levels decline, asparagine becomes an essential amino acid. Cell Metabolism. 27(2):428PubMedPubMedCentral Pavlova NN, Hui S, Ghergurovich JM, Fan J, Intlekofer AM, White RM et al (2018) As extracellular glutamine levels decline, asparagine becomes an essential amino acid. Cell Metabolism. 27(2):428PubMedPubMedCentral
26.
Zurück zum Zitat Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D et al (2005) GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22(5):633–642PubMed Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D et al (2005) GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22(5):633–642PubMed
27.
Zurück zum Zitat Van de Velde LA, Guo XJ, Barbaric L, Smith AM, Oguin TH 3rd, Thomas PG et al (2016) Stress kinase GCN2 controls the proliferative fitness and trafficking of cytotoxic T cells independent of environmental amino acid sensing. Cell Rep 17(9):2247–2258PubMedPubMedCentral Van de Velde LA, Guo XJ, Barbaric L, Smith AM, Oguin TH 3rd, Thomas PG et al (2016) Stress kinase GCN2 controls the proliferative fitness and trafficking of cytotoxic T cells independent of environmental amino acid sensing. Cell Rep 17(9):2247–2258PubMedPubMedCentral
28.
Zurück zum Zitat Keil M, Sonner JK, Lanz TV, Oezen I, Bunse T, Bittner S et al (2016) General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation. J Neuroimmunol 297:117–126PubMed Keil M, Sonner JK, Lanz TV, Oezen I, Bunse T, Bittner S et al (2016) General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation. J Neuroimmunol 297:117–126PubMed
29.
Zurück zum Zitat Nakamura A, Nambu T, Ebara S, Hasegawa Y, Toyoshima K, Tsuchiya Y et al (2018) Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response. Proc Natl Acad Sci USA 115(33):E7776–E7785PubMed Nakamura A, Nambu T, Ebara S, Hasegawa Y, Toyoshima K, Tsuchiya Y et al (2018) Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response. Proc Natl Acad Sci USA 115(33):E7776–E7785PubMed
30.
Zurück zum Zitat Nguyen HG, Conn CS, Kye Y, Xue LR, Forester CM, Cowan JE et al (2018) Development of a stress response therapy targeting aggressive prostate cancer. Sci Trans Med 10(439):eaar2036 Nguyen HG, Conn CS, Kye Y, Xue LR, Forester CM, Cowan JE et al (2018) Development of a stress response therapy targeting aggressive prostate cancer. Sci Trans Med 10(439):eaar2036
31.
Zurück zum Zitat Kim JW, Miska J, Young JS, Rashidi A, Kane JR, Panek WK et al (2017) A comparative study of replication-incompetent and -competent adenoviral therapy-mediated immune response in a murine glioma model. Mol Ther Oncolytics 5:97–104PubMedPubMedCentral Kim JW, Miska J, Young JS, Rashidi A, Kane JR, Panek WK et al (2017) A comparative study of replication-incompetent and -competent adenoviral therapy-mediated immune response in a murine glioma model. Mol Ther Oncolytics 5:97–104PubMedPubMedCentral
32.
Zurück zum Zitat Wu YM, Li L (2016) Sample normalization methods in quantitative metabolomics. J Chromatogr A 1430:80–95PubMed Wu YM, Li L (2016) Sample normalization methods in quantitative metabolomics. J Chromatogr A 1430:80–95PubMed
33.
Zurück zum Zitat Clarke SRM, Barnden M, Kurts C, Carbone FR, Miller JF, Heath WR (2000) Characterization of the ovalbumin-specific TCR transgenic line OT-I: MHC elements for positive and negative selection. Immunol Cell Biol 78(2):110–117PubMed Clarke SRM, Barnden M, Kurts C, Carbone FR, Miller JF, Heath WR (2000) Characterization of the ovalbumin-specific TCR transgenic line OT-I: MHC elements for positive and negative selection. Immunol Cell Biol 78(2):110–117PubMed
34.
Zurück zum Zitat Bjorkdahl O, Barber KA, Brett SJ, Daly MG, Plumpton C, Elshourbagy NA et al (2003) Characterization of CC-chemokine receptor 7 expression on murine T cells in lymphoid tissues. Immunology 110(2):170–179PubMedPubMedCentral Bjorkdahl O, Barber KA, Brett SJ, Daly MG, Plumpton C, Elshourbagy NA et al (2003) Characterization of CC-chemokine receptor 7 expression on murine T cells in lymphoid tissues. Immunology 110(2):170–179PubMedPubMedCentral
35.
Zurück zum Zitat Ladomersky E, Zhai L, Lenzen A, Lauing KL, Qian J, Scholtens DM et al (2018) IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma. Clin Cancer Res 24(11):2559–2573PubMedPubMedCentral Ladomersky E, Zhai L, Lenzen A, Lauing KL, Qian J, Scholtens DM et al (2018) IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma. Clin Cancer Res 24(11):2559–2573PubMedPubMedCentral
36.
Zurück zum Zitat Sonner JK, Deumelandt K, Ott M, Thome CM, Rauschenbach KJ, Schulz S et al (2016) The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas. Oncoimmunology 5(12):e1240858PubMedPubMedCentral Sonner JK, Deumelandt K, Ott M, Thome CM, Rauschenbach KJ, Schulz S et al (2016) The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas. Oncoimmunology 5(12):e1240858PubMedPubMedCentral
37.
Zurück zum Zitat Hayashi K, Altman A (2007) Protein kinase C theta (PKCtheta): a key player in T cell life and death. Pharmacol Res 55(6):537–544PubMedPubMedCentral Hayashi K, Altman A (2007) Protein kinase C theta (PKCtheta): a key player in T cell life and death. Pharmacol Res 55(6):537–544PubMedPubMedCentral
39.
Zurück zum Zitat Behrens PF, Langemann H, Strohschein R, Draeger J, Hennig J (2000) Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study. J Neurooncol 47(1):11–22PubMed Behrens PF, Langemann H, Strohschein R, Draeger J, Hennig J (2000) Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study. J Neurooncol 47(1):11–22PubMed
40.
Zurück zum Zitat Wibom C, Surowiec I, Moren L, Bergstrom P, Johansson M, Antti H et al (2010) Metabolomic patterns in glioblastoma and changes during radiotherapy: a clinical microdialysis study. J Proteome Res 9(6):2909–2919PubMed Wibom C, Surowiec I, Moren L, Bergstrom P, Johansson M, Antti H et al (2010) Metabolomic patterns in glioblastoma and changes during radiotherapy: a clinical microdialysis study. J Proteome Res 9(6):2909–2919PubMed
41.
Zurück zum Zitat Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R et al (2015) Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162(6):1217–1228PubMedPubMedCentral Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R et al (2015) Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162(6):1217–1228PubMedPubMedCentral
42.
Zurück zum Zitat Chang CH, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD et al (2015) Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162(6):1229–1241PubMedPubMedCentral Chang CH, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD et al (2015) Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162(6):1229–1241PubMedPubMedCentral
43.
Zurück zum Zitat Hayashi K, Jutabha P, Endou H, Sagara H, Anzai N (2013) LAT1 is a critical transporter of essential amino acids for immune reactions in activated human T cells. J Immunol 191(8):4080–4085PubMed Hayashi K, Jutabha P, Endou H, Sagara H, Anzai N (2013) LAT1 is a critical transporter of essential amino acids for immune reactions in activated human T cells. J Immunol 191(8):4080–4085PubMed
44.
Zurück zum Zitat Nawashiro H, Otani N, Uozumi Y, Ooigawa H, Toyooka T, Suzuki T et al (2005) High expression of L-type amino acid transporter 1 in infiltrating glioma cells. Brain Tumor Pathol 22(2):89–91PubMed Nawashiro H, Otani N, Uozumi Y, Ooigawa H, Toyooka T, Suzuki T et al (2005) High expression of L-type amino acid transporter 1 in infiltrating glioma cells. Brain Tumor Pathol 22(2):89–91PubMed
45.
Zurück zum Zitat Kobayashi K, Ohnishi A, Promsuk J, Shimizu S, Kanai Y, Shiokawa Y et al (2008) Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells. Neurosurgery. 62(2):493–503 (discussion -4) PubMed Kobayashi K, Ohnishi A, Promsuk J, Shimizu S, Kanai Y, Shiokawa Y et al (2008) Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells. Neurosurgery. 62(2):493–503 (discussion -4) PubMed
46.
Zurück zum Zitat Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Yang THO et al (2018) The immune landscape of cancer. Immunity. 48(4):812PubMedPubMedCentral Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Yang THO et al (2018) The immune landscape of cancer. Immunity. 48(4):812PubMedPubMedCentral
47.
Zurück zum Zitat Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B et al (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol 24(6):311–335PubMedPubMedCentral Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B et al (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol 24(6):311–335PubMedPubMedCentral
48.
Zurück zum Zitat Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J et al (2013) Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86(2):343–349PubMedPubMedCentral Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J et al (2013) Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86(2):343–349PubMedPubMedCentral
49.
Zurück zum Zitat Kleijn A, van den Bossche W, Haefner ES, Belcaid Z, Burghoorn-Maas C, Kloezeman JJ et al (2017) The sequence of Delta24-RGD and TMZ administration in malignant glioma affects the role of CD8(+)T cell anti-tumor activity. Mol Ther Oncolytics 5:11–19PubMedPubMedCentral Kleijn A, van den Bossche W, Haefner ES, Belcaid Z, Burghoorn-Maas C, Kloezeman JJ et al (2017) The sequence of Delta24-RGD and TMZ administration in malignant glioma affects the role of CD8(+)T cell anti-tumor activity. Mol Ther Oncolytics 5:11–19PubMedPubMedCentral
50.
Zurück zum Zitat Cao Y, Rathmell JC, Macintyre AN (2014) Metabolic reprogramming towards aerobic glycolysis correlates with greater proliferative ability and resistance to metabolic inhibition in CD8 versus CD4 T cells. PLoS One 9(8):e104104PubMedPubMedCentral Cao Y, Rathmell JC, Macintyre AN (2014) Metabolic reprogramming towards aerobic glycolysis correlates with greater proliferative ability and resistance to metabolic inhibition in CD8 versus CD4 T cells. PLoS One 9(8):e104104PubMedPubMedCentral
51.
Zurück zum Zitat Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH et al (2018) Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med 24(9):1459–1468PubMedPubMedCentral Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH et al (2018) Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med 24(9):1459–1468PubMedPubMedCentral
52.
Zurück zum Zitat Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL (1999) Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189(9):1363–1372PubMedPubMedCentral Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL (1999) Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189(9):1363–1372PubMedPubMedCentral
53.
Zurück zum Zitat Prendergast GC, Malachowski WP, DuHadaway JB, Muller AJ (2017) Discovery of IDO1 inhibitors: from bench to bedside. Cancer Res 77(24):6795–6811PubMedPubMedCentral Prendergast GC, Malachowski WP, DuHadaway JB, Muller AJ (2017) Discovery of IDO1 inhibitors: from bench to bedside. Cancer Res 77(24):6795–6811PubMedPubMedCentral
54.
Zurück zum Zitat Galezowski M, Sitarz K, Majewska E, Chmielewski S, Michalik K, Masiejczyk M et al (2017) Development of small molecule selective inhibitors of GCN2 as an immunotherapy aimed at preventing immune escape of tumor cells. Cancer Res 77:2639 Galezowski M, Sitarz K, Majewska E, Chmielewski S, Michalik K, Masiejczyk M et al (2017) Development of small molecule selective inhibitors of GCN2 as an immunotherapy aimed at preventing immune escape of tumor cells. Cancer Res 77:2639
55.
Zurück zum Zitat Wek RC, Jiang HY, Anthony TG (2006) Coping with stress: eIF2 kinases and translational control. Biochem Soc T 34:7–11 Wek RC, Jiang HY, Anthony TG (2006) Coping with stress: eIF2 kinases and translational control. Biochem Soc T 34:7–11
56.
Zurück zum Zitat B’chir W, Maurin AC, Carraro V, Averous J, Jousse C, Muranishi Y et al (2013) The eIF2 alpha/ATF4 pathway is essential for stress-induced autophagy gene expression. Nucleic Acids Res. 41(16):7683–7699PubMedPubMedCentral B’chir W, Maurin AC, Carraro V, Averous J, Jousse C, Muranishi Y et al (2013) The eIF2 alpha/ATF4 pathway is essential for stress-induced autophagy gene expression. Nucleic Acids Res. 41(16):7683–7699PubMedPubMedCentral
57.
Zurück zum Zitat Xu XJ, Araki K, Li SZ, Han JH, Ye LL, Tan WG et al (2014) Autophagy is essential for effector CD8(+) T cell survival and memory formation. Nat Immunol 15(12):1152–1161PubMedPubMedCentral Xu XJ, Araki K, Li SZ, Han JH, Ye LL, Tan WG et al (2014) Autophagy is essential for effector CD8(+) T cell survival and memory formation. Nat Immunol 15(12):1152–1161PubMedPubMedCentral
58.
Zurück zum Zitat Wilson GJ, Bunpo P, Cundiff JK, Wek RC, Anthony TG (2013) The eukaryotic initiation factor 2 kinase GCN2 protects against hepatotoxicity during asparaginase treatment. Am J Physiol Endocrinol Metab 305(9):E1124–E1133PubMedPubMedCentral Wilson GJ, Bunpo P, Cundiff JK, Wek RC, Anthony TG (2013) The eukaryotic initiation factor 2 kinase GCN2 protects against hepatotoxicity during asparaginase treatment. Am J Physiol Endocrinol Metab 305(9):E1124–E1133PubMedPubMedCentral
59.
Zurück zum Zitat She P, Bunpo P, Cundiff JK, Wek RC, Harris RA, Anthony TG (2013) General control nonderepressible 2 (GCN2) kinase protects oligodendrocytes and white matter during branched-chain amino acid deficiency in mice. J Biol Chem 288(43):31250–31260PubMedPubMedCentral She P, Bunpo P, Cundiff JK, Wek RC, Harris RA, Anthony TG (2013) General control nonderepressible 2 (GCN2) kinase protects oligodendrocytes and white matter during branched-chain amino acid deficiency in mice. J Biol Chem 288(43):31250–31260PubMedPubMedCentral
60.
Zurück zum Zitat Chaudhary K, Shinde R, Liu HY, Gnana-Prakasam JP, Veeranan-Karmegam R, Huang L et al (2015) Amino acid metabolism inhibits antibody-driven kidney injury by inducing autophagy. J Immunol 194(12):5713–5724PubMedPubMedCentral Chaudhary K, Shinde R, Liu HY, Gnana-Prakasam JP, Veeranan-Karmegam R, Huang L et al (2015) Amino acid metabolism inhibits antibody-driven kidney injury by inducing autophagy. J Immunol 194(12):5713–5724PubMedPubMedCentral
61.
Zurück zum Zitat Xu Y, Poggio M, Jin HY, Shi Z, Forester CM, Wang Y et al (2019) Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nat Med 25(2):301–311PubMedPubMedCentral Xu Y, Poggio M, Jin HY, Shi Z, Forester CM, Wang Y et al (2019) Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nat Med 25(2):301–311PubMedPubMedCentral
Metadaten
Titel
GCN2 is essential for CD8+ T cell survival and function in murine models of malignant glioma
verfasst von
Aida Rashidi
Jason Miska
Catalina Lee-Chang
Deepak Kanojia
Wojciech K. Panek
Aurora Lopez-Rosas
Peng Zhang
Yu Han
Ting Xiao
Katarzyna C. Pituch
Julius W. Kim
Mahsa Talebian
Jawad Fares
Maciej S. Lesniak
Publikationsdatum
01.01.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 1/2020
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-019-02441-6

Weitere Artikel der Ausgabe 1/2020

Cancer Immunology, Immunotherapy 1/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.